Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > ATE has them all!
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(598)
•••
Comment by clubhouse19on Dec 16, 2020 4:04pm
161 Views
Post# 32121277

RE:ATE has them all!

RE:ATE has them all!Who are those institutional holders  ??

This is what is listed currently

  Shorts are the biggest holders...

Targeted Security Holder Results - 5 items
Name Shares Held % of OS Report Date Change
ALPHANORTH GROWTH FUND 81,000 0.04 20190630 new
SHORT POSITIONS - TSX / CSE 73,000 0.03 20201031 -5,553
SHORT POSITIONS - NASDAQ / NYSE 19,984 0.01 20201030 33
NEXT EDGE BIO-TECH PLUS FUND 0 0.00 20191231 -1,030,000
DUNDEE GLOBAL RESOURCE CLASS 0 0.00 20190630 -4,166,666


Actuarial wrote: Ingridents required to be success for a Bio company are not something completely being a mystry. Solid science + sufficient funding + strong management team = success. And, ATE has them all!

John Wallace (science) + $22M in the bank & US institutional investors (funding) + Joseph Stauffer (management) = FDA approval. Not every Bio company be able to put all the required ingridents together.

The future is bright and the path is clear for ATE. 2021 is the time for exploding. GLTA longs!


<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities